Anti-AKR1D1 Antibody Picoband® Fluoro647 Conjugated

Human delta (4) -3-oxosteroid 5-beta-reductase (steroid 5-beta-reductase) catalyzes 5-beta-reduction of bile acid intermediates and steroid hormones carrying a delta (4) -3-one structure. This gene is mapped to 7q33. The enzyme encoded by this gene is responsible for the catalysis of the 5-beta-reduction of bile acid intermediates and steroid hormones carrying a delta (4) -3-one structure. Deficiency of this enzyme may contribute to hepatic dysfunction. Three transcript variants encoding different isoforms have been found for this gene. Other variants may be present, but their full-length natures have not been determined yet.

3-oxo-5-beta-steroid 4-dehydrogenase; Aldo-keto reductase family 1 member D1; Delta (4) -3-ketosteroid 5-beta-reductase; Delta (4) -3-oxosteroid 5-beta-reductase; AKR1D1; SRD5B1

A synthetic peptide corresponding to a sequence at the C-terminus of human AKR1D1, which shares 90.9% and 93.9% amino acid (aa) sequence identity with mouse and rat AKR1D1, respectively.

Metabolic Signaling Pathways, Metabolism, Pathways and Processes, Signal Transduction, Cancer, Cardiovascular, Lipid and Lipoprotein Metabolism, Cancer Metabolism, Lipid Metabolism, Metabolic Signaling Pathway, Metabolism of Lipids and Lipoproteins, Cholesterol Metabolism, Lipids/Lipoproteins

Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-cholesten-3-one can also act as substrates.

1. Charbonneau, A., Luu-The, V. Assignment of steroid 5-beta-reductase (SRD5B1) and its pseudogene (SRD5BP1) to human chromosome bands 7q32-q33 and 1q23-q25, respectively, by in situ hybridization. Cytogenet. Cell Genet. 84: 105-106, 1999. 2. Charbonneau, A., The, V.-L. Genomic organization of a human 5-beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim. Biophys. Acta 1517: 228-235, 2001. 3. Clayton, P. T., Mills, K. A., Johnson, A. W., Barabino, A., Marazzi, M. G. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623-628, 1996.